Biocon Biologics Secures Insulins Supply Contract Extension from Malaysian MoH

Biocon Biologics Limited (BBL) has announced that the Government of Malaysia has agreed to extend the current contract period of 36 months under the existing insulin supply agreement with its subsidiary in Malaysia, Biocon Sdn. Bhd., and Duopharma Marketing Sdn. Bhd. (DMktg), for an additional six (6) months effective from April 29, 2025 until October 28, 2025. The company, which has been serving patients in Malaysia for nearly 10 years, manufactures a range of recombinant human insulin products at its state-of-the-art facility in Johor, Malaysia. These insulin products are distributed in Malaysia through its commercial partner DMktg. The amendment to the contract will be formalised through the execution of a formal supplementary agreement between the MoH, DMktg and Biocon subsequently. BBL remains committed to enabling affordable access to life-saving insulins to people with diabetes in Malaysia and other parts of the world.